Micardis

Telmisartan, the active ingredient in Micardis, is an Angiotensin II receptor blocker (ARB) presented as an oral tablet for oral use. It is prescribed to lower elevated blood pressure in adult patients and helps reduce the risk of cardiovascular complications associated with hypertension.

GNH USA supplies Micardis as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with a focus on quality assurance and regulatory compliance, and a distribution network that ensures timely delivery across multiple regions.

Micardis (telmisartan) acts on the renin‑angiotensin‑aldosterone system to control high blood pressure.

Hypertension: reduces systolic and diastolic blood pressure in patients with primary (essential) hypertension, contributing to decreased risk of stroke, myocardial infarction, and other hypertension‑related cardiovascular events. Essential hypertension: provides long‑lasting blood pressure control, improving overall cardiovascular health and reducing the need for additional antihypertensive agents.

Telmisartan may cause a range of adverse reactions, which are generally classified by frequency.

Common Side Effects: - Dizziness - Headache - Fatigue

Serious or Rare Side Effects: - Angioedema - Renal impairment - Hyperkalemia

Before initiating therapy, clinicians should consider several safety measures.

Monitor blood pressure: ensure adequate control and avoid excessive hypotension. Assess renal function: check serum creatinine and eGFR periodically. Check serum potassium: monitor for hyperkalemia, especially with concomitant potassium‑sparing agents. Use caution in hepatic impairment: dose adjustments may be required. Avoid concurrent aliskiren in diabetic patients: increased risk of adverse renal outcomes. Store at room temperature: keep in the original pack, protect from moisture.

Telmisartan can interact with several medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Aliskiren: combined use may cause renal dysfunction and hyperkalemia. - Potassium‑sparing diuretics or supplements: risk of dangerous hyperkalemia. - ACE inhibitors: concurrent use can increase the likelihood of angioedema and hyperkalemia.

Moderate Interactions (Monitor Closely): - NSAIDs: may blunt antihypertensive effect and affect renal function. - CYP3A4 inducers (e.g., rifampin): can lower telmisartan plasma concentrations. - Lithium: may increase lithium levels, necessitating serum monitoring.